BioCentury
ARTICLE | Company News

Apricus Biosciences, Laboratoires Majorelle sales and marketing update

November 25, 2013 8:00 AM UTC

Apricus granted Majorelle exclusive rights to market Vitaros alprostadil in France, Monaco and certain African countries. Apricus is eligible to receive up to $4 million in upfront and regulatory milestone payments and up to about $21 million in sales milestone payments, plus double-digit tiered royalties on net sales in the territories.

Vitaros was approved to treat erectile dysfunction (ED) under Europe's decentralized procedure in June, with the Netherlands acting as the reference state. Concerned member states Germany, Ireland, the Netherlands, Sweden and the U.K. have approved the drug, which is still under review in France, Italy, Spain, Belgium and Luxembourg. Apricus said it is on track to receive the remainder of the approvals through 1Q14 and expects its partners to launch the product throughout 2014. Apricus expects to close partnering negotiations in 4Q13 for Vitaros for the remaining unpartnered territories in Europe, Latin America and parts of Africa. ...